Tests for detection of hot spot mutations and methylation of Retinoblastoma-like 2 gene (RBL2) as diagnostic and prognostic markers of tumors (Brevetto)

Type
Label
  • Tests for detection of hot spot mutations and methylation of Retinoblastoma-like 2 gene (RBL2) as diagnostic and prognostic markers of tumors (Brevetto) (literal)
Anno
  • 2006-01-01T00:00:00+01:00 (literal)
Alternative label
  • Cinti C.; La Sala D. (2006)
    Tests for detection of hot spot mutations and methylation of Retinoblastoma-like 2 gene (RBL2) as diagnostic and prognostic markers of tumors
    (literal)
Titolo
  • Tests for detection of hot spot mutations and methylation of Retinoblastoma-like 2 gene (RBL2) as diagnostic and prognostic markers of tumors (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Cinti C.; La Sala D. (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni
  • The invention relates generally to cancer markers, and more specificaly to cancer markers obtained fron CpG rich regione of genes that are susceptible to methylation, in order to allow evaluating a gene methylation whithin a sample, and to detect conditions associated with the methylation status of a gene. (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#proprieta
  • CNR (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://puma.isti.cnr.it/linkres.php?resource=cnr.ifc/cnr.ifc/2006-BV-004 (literal)
Http://www.cnr.it/ontology/cnr/brevetti.owl#tipoDiBrevetto
  • Internazionale (literal)
Numero brevetto
  • WO2007137597 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note
  • Patent n. WO2007137597, Pisa. Registered on 2007-12-12. (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto
  • The present invention utilizes human gene sequence, a specific CpG island of RBL2 retinoblastoma-like 2 (pl30) gene, and designs primers based on base mismatch principle selected to constitute CpG island methylation test reagent kit for diagnosing tumor and screening demethylation medicine. The reagent kit includes primers specific for MSP- PCR reaction system. The complete CpG island sensitive to methylation is also provide. Moreover specific primers for detection of \"hot-spot\" mutations at exon 1, identified as tumor biomarkers and the PCR reaction are provided. Three RBL2 retinoblastoma-like 2 (pl30) regions rich in CpG dinucleotide, the promoter region immediately 5'- flanking to the transcription start site (ATG) , the exon 1 and the intron 1, are target to epigenetic events in tumors. Two specific exon 1 mutations, inside a CpG region sensitive to methylation, are present in different cancer hystotype representing tumor-specific marker. Analysis of methylation patterns in the RBL2 retinoblastoma-like 2 (pl30) regions rich in CpG dinucleotide by Methylation Specific PCR (MSP) and mutational analysis of exon 1 provide methods for diagnosis and prognosis and for targeting therapy in cancer patients. (literal)
Anno di deposito
  • 2006 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Istituto di Fisiologia Clinica, Sezione di Siena (literal)
Titolo
  • Tests for detection of hot spot mutations and methylation of Retinoblastoma-like 2 gene (RBL2) as diagnostic and prognostic markers of tumors (literal)
Http://www.cnr.it/ontology/cnr/brevetti.owl#trasferimentoBrevetto
  • previsto (literal)
Http://www.cnr.it/ontology/cnr/brevetti.owl#annoDiConcessione
  • 2007 (literal)
Abstract
  • Three RBL2 retinoblastoma-like 2 (p130) regions rich in CpG dinucleotide, the promoter region immediately 5‚-flanking to the transcription start site (ATG), the exon 1 and the intron 1, are target to epigenetic events in tumors. Two specific exon 1 mutations, inside a CpG region sensitive to methylation, are present in different cancer hystotype representing tumor-specific marker. Analysis of methylation patterns in the RBL2 retinoblastoma-like 2 (p130) regions rich in CpG dinucleotide by Methylation Specific PCR (MSP) and mutational analysis of exon 1 provide methods for diagnosis and prognosis and for targeting therapy in cancer patients. The present invention utilizes human gene sequence, a specific CpG island of RBL2 retinoblastoma-like 2 (p130) gene, and designs primers based on base mismatch principle selected to constitute CpG island methylation test reagent kit for diagnosing tumor and screening demethylation medicine. The reagent kit includes primers specific for MSP-PCR reaction system. The complete CpG island sensitive to methylation is also provide. Moreover specific primers for detection of hot-spot mutations at exon 1, identified as tumor biomarkers and the PCR reaction are provided. Its application serves as biomarkers for early detection of cancer, for risk assessment and for predicting response to therapy. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Insieme di parole chiave di
data.CNR.it